1. Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.
- Author
-
Xing SS, Shen CC, Godard MP, Wang JJ, Yue YY, Yang ST, Zhao Q, Zhang SB, Wang TX, Yang XL, Delafontaine P, He Y, and Song YH
- Subjects
- Animals, Bortezomib, Cell Line, Cell Survival drug effects, Down-Regulation drug effects, Extracellular Signal-Regulated MAP Kinases genetics, Mice, Muscle Fibers, Skeletal cytology, Muscle Fibers, Skeletal metabolism, Apoptosis drug effects, Boronic Acids pharmacology, G2 Phase Cell Cycle Checkpoints drug effects, M Phase Cell Cycle Checkpoints drug effects, Muscle Fibers, Skeletal drug effects, Proteasome Inhibitors pharmacology, Pyrazines pharmacology
- Abstract
Proteosome inhibitors such as bortezomib (BTZ) have been used to treat muscle wasting in animal models. However, direct effect of BTZ on skeletal muscle cells has not been reported. In the present study, our data showed that C2C12 cells exhibited a dose-dependent decrease in cell viability in response to increasing concentrations of BTZ. Consistent with the results of cell viability, Annexin V/PI analysis showed a significant increase in apoptosis after exposing the cells to BTZ for 24h. The detection of cleaved caspase-3 further confirmed apoptosis. The apoptosis induced by BTZ was associated with reduced expression of p-ERK. Cell cycle analysis revealed that C2C12 cells underwent G2/M cell cycle arrest when incubated with BTZ for 24h. Furthermore, BTZ inhibited formation of multinucleated myotubes. The inhibition of myotube formation was accompanied by decreased expression of Myogenin. Our data suggest that BTZ induces cell death and inhibits differentiation of C2C12 cells at clinically relevant doses., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF